Cibisatamab Biosimilar – Anti-CEACAM5&CD3E;CD3E mAb – Research Grade from ProteoGenix; catalogue PX-TA1824; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Cibisatamab Biosimilar, also known as Anti-CEACAM5&CD3E,CD3E mAb, is a monoclonal antibody used for therapeutic purposes. It is a biosimilar version of the original Cibisatamab, which is a fully humanized monoclonal antibody targeting CEACAM5 and CD3E antigens. This biosimilar version is produced through recombinant DNA technology and has shown promising results in preclinical and clinical studies. In this article, we will discuss the structure, activity, and potential applications of Cibisatamab Biosimilar.
Cibisatamab Biosimilar is a chimeric monoclonal antibody, meaning it is composed of both human and non-human components. It is made up of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains are approximately 50 kDa in size, while the light chains are around 25 kDa. The antibody has a molecular weight of approximately 150 kDa.
The variable regions of Cibisatamab Biosimilar are derived from a mouse monoclonal antibody, while the constant regions are from a human immunoglobulin G1 (IgG1) antibody. This structure allows for high specificity and affinity towards its target antigens.
Cibisatamab Biosimilar works by binding to two different antigens, CEACAM5 and CD3E, on the surface of cancer cells. CEACAM5 is a glycoprotein that is overexpressed in many types of cancer, including colorectal, lung, and breast cancer. CD3E is a protein found on the surface of T cells, a type of immune cell. By targeting both antigens, Cibisatamab Biosimilar can activate T cells to attack and kill cancer cells.
Once bound to its target antigens, Cibisatamab Biosimilar triggers a cascade of immune responses, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These mechanisms work by recruiting other immune cells and proteins to destroy the targeted cancer cells.
Cibisatamab Biosimilar is currently being investigated for its potential use in the treatment of various types of cancer. Preclinical studies have shown promising results in colorectal, lung, and breast cancer models. In a phase 1 clinical trial, Cibisatamab Biosimilar showed promising results in patients with advanced solid tumors, including those with colorectal cancer.
In addition to its potential as a monotherapy, Cibisatamab Biosimilar is also being studied in combination with other cancer treatments. For example, it is being investigated in combination with chemotherapy for the treatment of colorectal cancer, and with immune checkpoint inhibitors for the treatment of lung cancer.
In conclusion, Cibisatamab Biosimilar is a chimeric monoclonal antibody that targets CEACAM5 and CD3E antigens on the surface of cancer cells. Its unique structure and mechanism of action make it a promising therapeutic option for various types of cancer. Further research and clinical trials are needed to fully understand the potential of this biosimilar in cancer treatment.
ProteoGenix catalogue number PX-TA1824. For research use only.
Target: Cibisatamab Biosimilar – Anti-CEACAM5&CD3E;CD3E mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Cibisatamab Biosimilar – Anti-CEACAM5&CD3E;CD3E mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
